Wouter L J Hinrichs
Overview
Explore the profile of Wouter L J Hinrichs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
1118
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jansen E, van der Koog L, Elferink R, Rafie K, Nagelkerke A, Gosens R, et al.
Small
. 2025 Feb;
:e2411096.
PMID: 39945036
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, with a significant impact on low- and middle-income countries, making it a critical challenge for global health...
2.
Visscher M, Frijlink H, Hinrichs W
Pharmaceutics
. 2025 Jan;
17(1).
PMID: 39861771
The application of dissolving microneedle arrays (DMNAs) is an emerging trend in drug and vaccine delivery as an alternative for hypodermic needles or other less convenient drug administration methods. The...
3.
Heida R, Jacob Silva P, Akkerman R, Moser J, De Vries-Idema J, Bornet A, et al.
Eur J Pharm Biopharm
. 2024 Sep;
204:114507.
PMID: 39303952
Increasing resistance to antiviral drugs approved for the treatment of influenza urges the development of novel compounds. Ideally, this should be complemented by a careful consideration of the administration route....
4.
Putri K, Adhyatmika A, Boorsma C, Habibie H, Ruigrok M, Heukels P, et al.
Lung
. 2024 Apr;
202(3):331-342.
PMID: 38642135
Background: Lung fibrosis is a chronic lung disease with a high mortality rate with only two approved drugs (pirfenidone and nintedanib) to attenuate its progression. To date, there are no...
5.
T T Nguyen K, Zillen D, Lasorsa A, van der Wel P, Frijlink H, Hinrichs W
Int J Pharm
. 2024 Feb;
654:123938.
PMID: 38408554
The stability of lactate dehydrogenase (LDH) and β-galactosidase (β-gal), incorporated in arginine/pullulan (A/P) mixtures at various weight ratios by lyophilization, was determined. The physicochemical characteristics of various A/P mixtures were...
6.
Heida R, Frijlink H, Hinrichs W
mBio
. 2023 Sep;
14(5):e0129523.
PMID: 37768057
Many of the current pandemic threats are caused by viruses that infect the respiratory tract. Remarkably though, the majority of vaccines and antiviral drugs are administered via alternative routes. In...
7.
T T Nguyen K, Zillen D, van Heijningen F, van Bommel K, van Ee R, Frijlink H, et al.
Pharmaceutics
. 2023 Sep;
15(9).
PMID: 37765163
In a previous attempt to achieve ileo-colonic targeting of bovine intestinal alkaline phosphatase (BIAP), we applied a pH-dependent coating, the ColoPulse coating, directly on powder bed printed (PBP) tablets. However,...
8.
Lee J, Beukema M, Zaplatynska O, OMahony C, Hinrichs W, Huckriede A, et al.
Biomater Sci
. 2023 Aug;
11(20):6790-6800.
PMID: 37622228
Dissolving microneedle arrays (dMNAs) can be used to deliver vaccines the intradermal route. Fabrication of dMNAs using centrifugation is the most common preparation method of dMNAs, but it results in...
9.
Heida R, Hagedoorn P, van Meel M, Prins J, Simonis F, Akkerman R, et al.
Pharmaceutics
. 2023 Jul;
15(7).
PMID: 37514034
A challenge in the development of dry powder formulations for inhalation is the poor reproducibility of their administration to small laboratory animals. The currently used devices for the pulmonary administration...
10.
Heida R, Akkerman R, Jacob Silva P, Lakerveld A, Ortiz D, Bigogno C, et al.
J Control Release
. 2023 Apr;
357:264-273.
PMID: 37015293
Respiratory viruses including the respiratory syncytial virus (RSV) aggravate the global burden of virus-inflicted morbidity and mortality. Entry inhibitors are a promising class of antiviral drugs for combating these viruses,...